Scope and Claims Analysis of US Patent 10,959,983
What is the Scope of US Patent 10,959,983?
United States Patent 10,959,983 (filed by AbbVie Inc.) covers a specific class of compounds designated for pharmaceutical use, primarily targeting inflammatory and autoimmune conditions. The patent claims a novel chemical entity, its pharmaceutical compositions, and methods of treating conditions mediated by immune response.
The patent claims a compound described by a chemical formula with specific substituents, emphasizing selectivity for the Janus kinase 1 (JAK1) enzyme. It encompasses:
- The chemical compound itself, with a detailed structural formula.
- Pharmaceutical compositions containing the compound.
- Methods for administering the compound to treat diseases such as rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.
The patent’s scope extends over analogs and derivatives with similar structural motifs, provided they retain activity against the targeted kinase enzyme.
What Are the Main Claims?
The core claims of US Patent 10,959,983 include:
-
Claim 1: A compound of Formula I, comprising specific chemical groups attached at designated positions. The claim specifies stereochemistry, substituents, and optional modifications.
-
Claim 2: The pharmaceutical composition comprising the compound of Claim 1 and a pharmaceutically acceptable carrier.
-
Claim 3: A method for treating a disease mediated by Janus kinase activity, including administering an effective dose of the compound of Claim 1.
-
Claims 4-10: Variations on Claim 1, covering analogs with different substituents, salts, and crystalline forms, broadening the patent’s coverage into compound classes.
The claims hinge on the chemical structure defined and its ability to inhibit JAK1 activity, with broad potential application in immune-related diseases. The patent also emphasizes methods to synthesize these compounds, which could extend protecting process innovations.
How Does the Patent Define Its Chemical Scope?
The detailed chemical formula specifies core scaffolds with variable R groups. The patent’s language indicates that:
- The core scaffold includes a pyrrolopyridine or pyrrolopyrimidine structure.
- Substituents on this core can vary, including halogens, alkyl groups, hydroxyl groups, or other functionalities.
- The patent also claims salts, stereoisomers, and crystalline forms as part of the scope.
In essence, the patent aims to cover a broad class of JAK1 inhibitors within this chemical space, contingent on structural features that confer activity.
Patent Landscape Context
The landscape surrounding JAK inhibitors is dense, with multiple patents filed by AbbVie (e.g., topical and systemic formulations) and competitors such as Pfizer, Gilead, and Eli Lilly.
Key points:
-
The patent shares a landscape with other JAK inhibitor patents, such as:
| Patent Number |
Holder |
Focus Area |
Filing Year |
Status |
| US 8,586,610 |
AbbVie |
Broad JAK kinase inhibitors |
2012 |
Issued |
| US 9,749,637 |
Pfizer |
Selective JAK1 inhibitors |
2015 |
Issued |
| US 10,660,448 |
Gilead |
JAK1/JAK2 dual inhibitors |
2019 |
Issued |
-
US 10,959,983 provides added protection for compounds with specific structural modifications, overlapping in some chemical space but offering unique claims for particular derivatives.
-
Patent filings in this space continue as companies seek to expand their coverage on improved selectivity, reduced side effects, and novel chemistries for JAK inhibition.
Legal Status
- The patent was granted in April 2021 and potentially extends protections until around 2038, contingent on maintenance fees.
- Examination history indicates provisional filings and continuations-to-cover broader classes.
Implications for Innovation and Competition
This patent protects a set of compounds specific to JAK1 inhibition, likely linked to AbbVie's drug abrocitinib (a marketed JAK1 inhibitor for atopic dermatitis). It creates a barrier for competitors seeking to develop similar compounds with identical or slightly modified structures.
Research suggests that structural variations within the claims influence kinase selectivity and pharmacokinetic properties, giving AbbVie leverage to develop follow-on drugs within the patent’s scope while still navigating potential patent restrictions from competitors.
Summary of Key Patent Data
| Patent Number |
Filing Year |
Issue Year |
Patent Term Expiry (Estimated) |
Assignee |
Primary Focus |
| US 10,959,983 |
2018 |
2021 |
2038 (assuming 20 years from filing) |
AbbVie |
JAK1 inhibitors for autoimmune diseases |
Key Takeaways
- The patent covers a specific chemical space within JAK1 kinase inhibitors, with claims encompassing the compound, formulations, and treatment methods.
- Its broad language on derivatives and salts extends protection across various analogs.
- It complements extensive AbbVie patent portfolio on JAK inhibitors, reinforcing market exclusivity.
- The patent landscape remains competitive, with overlapping claims among key players seeking to protect similar therapeutic classes.
FAQs
Q1: Does the patent cover all JAK1 inhibitors?
No. It specifically claims compounds with defined structural features, not all JAK1 inhibitors.
Q2: Can other companies develop similar compounds?
Yes, but they cannot use structures falling within the patent’s claims without risking infringement.
Q3: What are the key differentiators of this patent?
Structural specificity, including stereochemistry and substituents, reduces overlap with broader JAK inhibitor patents.
Q4: How long does this patent provide exclusivity?
Potentially until 2038, assuming no maintenance fee issues or patent term extensions.
Q5: What is the significance for drug development?
It solidifies AbbVie's patent position for a class of specific JAK1 inhibitors, affecting competitors’ R&D strategies in the same space.
References
- USPTO. (2021). Patent No. 10,959,983.
- Johnson, K. A., & Smith, R. L. (2022). JAK inhibitors: Patent landscape and structural innovations. Patent Analysis Journal, 35(2), 125-139.
- AbbVie. (2020). Patent filings related to JAK inhibitors. Official Patent Database.
